I-Mab(US:IMAB) Jin Rong Jie·2025-08-21 14:36Core Viewpoint - Tianjing Bio (IMAB) has shown significant growth in revenue and is preparing to release its fiscal year 2024 mid-term report, indicating a focus on innovative biopharmaceuticals in oncology and autoimmune diseases [1][2]. Financial Performance - As of December 31, 2023, Tianjing Bio reported total revenue of 27.644 million RMB, representing a year-on-year increase of 112.48% [1]. - The company recorded a net profit attributable to shareholders of -1.466 billion RMB, which is a year-on-year increase of 41.54% [1]. Upcoming Events - Tianjing Bio is scheduled to disclose its fiscal year 2024 mid-term report on August 28, 2023, before the market opens in the Eastern US [1]. Company Overview - Tianjing Bio is an offshore holding company that operates through its domestic subsidiary, focusing on developing innovative biopharmaceuticals with "first-in-class" and "best-in-class" potential [1]. - The company's mission is to create groundbreaking innovative biopharmaceuticals to address unmet clinical needs and improve the quality of life for patients globally [1].